Simulations Plus completes USD 376.8 million merger, taking Simulations Plus stock private

Published on 10/16/2026 at 05:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Shareholders received USD 18.50 per share on October 6, 2026. Simulations Plus stock is private after Nasdaq delisting in a USD 376.8 million deal.

Deal terms and ownership change

On October 6, 2026, the merger valued Simulations Plus at USD 376.8 million.
The merger agreement was dated June 15, 2026.
Eligible shareholders received USD 18.50 per share in cash.

SLP, US8292141053, Illustration mit AI erstellt.

Simulations Plus (ISIN US8292141053) completed a USD 376.8 million merger on October 6, 2026, with each eligible share converted into USD 18.50 in cash, according to the SEC. The transaction made Simulations Plus a wholly owned subsidiary of an Altaris affiliate and ended its public-market status.

Private ownership replaces Nasdaq trading

Yahoo Finance, carrying a Business Wire release dated October 6, 2026, reported that Simulations Plus would no longer trade on the Nasdaq Global Select Market. The company is being combined with Chemical Computing Group, an Altaris portfolio company focused on molecular modeling and drug discovery software.

The cash consideration fixes the outcome for eligible shareholders at USD 18.50 per share. The filing also states that options with exercise prices at or above USD 18.50 were canceled without consideration, while qualifying lower-strike options were converted into cash rights.

Three steps led to the closing

The chronology is clear: the merger agreement was dated June 15, 2026, the transaction was announced on June 16, 2026, and the merger closed on October 6, 2026. The closing filing assigns the deal a total value of USD 376.8 million and says Simulations Plus continued under its own name within the combined business.

What changes for shareholders?

Shareholders ceased to have equity rights at the effective time apart from receiving the USD 18.50 cash consideration. The same filing records a change of control, the departure of four directors and the appointment of Paul Labute as president on October 6, 2026.

Ownership now drives the outlook

Simulations Plus is now privately held, so the former SLP listing no longer provides a public equity price or regular exchange trading. Its software portfolio remains centered on model-informed drug development, pharmacometrics, toxicology and AI-enabled drug design, while the combined platform is intended to span drug discovery, modeling, simulation and development.